SCHEMBL23705674

SCHEMBL23705674

COC(=O)C1OCc2c(OC)cc(Br)cc2C1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
CYP2C19 P33261 1/20 0.37
PIM1 P11309 1/20 0.34
FAAH O00519 2/20 0.34
CNR2 P34972 1/20 0.34
ALDH1A1 P00352 3/20 0.33
HSD17B10 Q99714 3/20 0.33
KDM4E B2RXH2 2/20 0.33
HPGD P15428 2/20 0.33
LMNA P02545 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAPT P10636 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
GFER P55789 1/20 0.32
ERN1 O75460 1/20 0.32
STAT1 P42224 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23714843 0.86 HPGD (0.33) CYP1A2KMT2AMEN1CYP2C19HPGD
SCHEMBL23704928 0.85 ALDH1A1 (0.33) ALDH1A1
SCHEMBL23704812 0.76 SLC6A4 (0.36) KMT2AMEN1CYP2C19ALDH1A1LMNA
SCHEMBL21505399 0.74 METAP1 (0.39) KMT2AMEN1CYP2C19ALDH1A1HSD17B10
SCHEMBL23704820 0.72 MAOB (0.36) CYP1A2KMT2AMEN1CYP2C19PIM1
SCHEMBL31064458 0.69 ALDH1A1 (0.30) ALDH1A1MAPT
SCHEMBL31554124 0.67 KMT2A (0.40) KMT2AALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL31554234 0.65 POLB (0.33)
SCHEMBL10048460 0.64 ELANE (0.39) KMT2AMEN1ALDH1A1CYP2C9MAPT
SCHEMBL286695 0.62 TSHR (0.43) CYP1A2CYP2C19KDM4ELMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 CN disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CYP1A2 3256/4885KMT2A 792/4885MEN1 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.